Welcome to our dedicated page for Neurogene news (Ticker: NGNE), a resource for investors and traders seeking the latest updates and insights on Neurogene stock.
Neurogene Inc. (Nasdaq: NGNE) generates news primarily around its gene therapy programs for rare neurological diseases, with a central focus on NGN-401 for Rett syndrome. As a clinical-stage company, Neurogene regularly issues updates on clinical trial progress, interim data, regulatory interactions and corporate developments.
Recent press releases highlight multiple milestones for NGN-401, including dosing of participants in the Embolden registrational trial, initiation of numerous U.S. clinical trial sites, and positive interim data from the Phase 1/2 trial in pediatric and adolescent/adult cohorts. These updates describe multidomain, durable functional gains and developmental milestone acquisition in females with Rett syndrome, along with safety observations at the 1E15 vg dose.
Visitors to this NGNE news page can review announcements on trial design for Embolden, preclinical data comparing intracerebroventricular and intrathecal lumbar delivery, and regulatory designations from the FDA, EMA and UK MHRA. Neurogene also reports on participation in healthcare and genetic medicines conferences, where management presents company overviews and clinical data, as well as on financial results and cash runway disclosures through quarterly earnings releases.
Additional news items cover corporate matters such as inducement grants under Nasdaq Listing Rule 5635(c)(4) and updates furnished via Form 8-K. For investors and followers of Rett syndrome research, the NGNE news stream provides a consolidated view of Neurogene’s clinical progress, regulatory status and operational execution around NGN-401 and its broader gene therapy platform over time.
Neurogene announced that the first patient in the high-dose cohort of their NGN-401 gene therapy trial for Rett syndrome has been dosed. Early data shows that high-dose NGN-401 is well-tolerated. Additionally, interim safety data from the low-dose cohort, shared at the IRSF ASCEND 2024 Summit, indicates a favorable safety profile with no new treatment-related adverse events (AEs). The company plans to release interim efficacy data from the low-dose cohort in Q4 2024 and is working with the FDA under its START Pilot Program to expedite NGN-401's development.
Neurogene (NASDAQ: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, announced participation in several upcoming conferences.
At the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, management will present a corporate overview and meet with investors.
On June 18-19, 2024, at the IRSF Rett Syndrome Scientific Meeting, interim safety data from the NGN-401 gene therapy trial for Rett syndrome will be presented by management and Dr. Bernhard Suter.
Additionally, Neurogene will participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit on June 21, 2024. Live webcasts of these events will be available on Neurogene’s Investor Relations webpage.
Neurogene (NASDAQ: NGNE) announced that its NGN-401 gene therapy for Rett syndrome has been chosen by the FDA for the START Pilot Program, aimed at accelerating the development of rare disease therapies. NGN-401 is one of only three programs selected by the CBER division, due to its potential clinical benefits and readiness for clinical development.
This selection allows Neurogene enhanced communication with the FDA to resolve product-specific development issues promptly. Currently, NGN-401 is being evaluated in a Phase 1/2 clinical trial, focusing on safety, tolerability, and preliminary efficacy in female pediatric patients. Interim efficacy data is expected in Q4 2024.
Neurogene recently reported favorable safety data from the first three patients dosed. The START Program aims to provide frequent FDA advice to facilitate the program's development and generate high-quality data for potential future marketing applications.
Neurogene Inc. (Nasdaq: NGNE) reported its first quarter 2024 financial results and highlighted recent corporate updates, focusing on the NGN-401 gene therapy trial for Rett syndrome. The company presented favorable safety data at the ASGCT Annual Meeting, received Australian HREC approval for the trial, and remains on track to provide interim efficacy data in Q4:24. Neurogene maintains a strong balance sheet with cash runway into 2H:26.
Neurogene Inc. presented favorable safety data from the Phase 1/2 trial of NGN-401 Gene Therapy for Rett Syndrome at the ASGCT Annual Meeting. The therapy was well-tolerated by the first three patients dosed, showing no signs of overexpression toxicity. The company remains on track to provide interim efficacy data in the fourth quarter of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.